Please assess the completion status of the following clinical trial:

Trial Title: The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Outpatients of at least 18 years of age~* History of GERD-related symptoms of at least 6 months prior to baseline visit~* Endoscopically-confirmed GERD or non-erosive GERD~Exclusion Criteria:~* Zollinger-Ellison syndrome or other gastric hypersecretory condition~* Acute peptic ulcer and/or ulcer complications~* Pyloric stenosis~* Severe or unstable cardiovascular, pulmonary, and/or endocrine disease~* Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of reliable contraception in women of child-bearing potential~* Intake of any medication for the purpose of eradication of Helicobacter pylori (H. pylori) within the last 28 days prior to study start~* Intake of systemic glucocorticoids or non-steroidal anti-inflammatory drugs including cyclooxygenase-2 (COX-2) inhibitors for more than 3 consecutive days within the last 28 days prior to study start; with the exception of acetylsalicylic acid not more than 150 mg per day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. (Type: ACTIVE_COMPARATOR): 40 mg Pantoprazole

Based on this trial design, predict the completion outcome and termination type (if applicable).